+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

M

Actively Recruiting

Healthy Volunteer

Researchers are conducting a multi-center clinical study to assess artificial intelligence AI algorithms for measuring heart function and size using echocardiography. The study aims to compare AI measurements with those of physicians at different experience levels, evaluate the accuracy and stability of AI, and explore its use in complex heart conditions like cardiomyopathy, valve disease, and coronary heart disease. The goal is to improve diagnostic consistency and clinical workflows across medical centers. The study involves measuring cardiac chamber size and function in 1600 participants using AI, senior physicians, and intermediate physicians. All measurements are made with Mindray ultrasonic machines. AI and intermediate physician results are completed within one day after data collection, while senior physician results are completed within one month. The study will establish a standardized reference system for AI-assisted echocardiographic measurements and evaluate AIs performance in special cases. Participants will undergo echocardiographic scans with measurements of left and right ventricular size and function, Doppler ultrasound indicators, and valve annulus displacements. Researchers will analyze data to compare AI and physician measurements, assess measurement deviations, and evaluate AIs efficiency in reducing analysis time. The study will run until July 2026, with ongoing data collection and analysis across multiple centers, aiming to promote wider clinical application of AI technology for cardiovascular disease diagnosis.

Age: 18Years - 80YearsAll Genders
37 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are conducting the China Cognition and Aging Study China COAST to understand dementia and its subtypes in China, including mild cognitive impairment MCI, sporadic and familial Alzheimers disease SAD and FAD, vascular dementia VaD, and other types. This large, national, multi-center, longitudinal observational study aims to build a comprehensive database to improve diagnosis, study the causes and genetic features, monitor disease progression, and evaluate prevention and treatment strategies, including non-drug interventions. The study also focuses on education, stigma, and management of dementia in the Chinese population. Participants include individuals with MCI, SAD, FAD, VaD, normal cognitive function, and other dementias recruited from both community and hospital populations. Researchers collect detailed demographic, clinical, genetic, imaging, and biological sample data. Study procedures include clinical evaluations, neuropsychological tests, imaging such as PETMR scans, and fluid biomarker analysis. The study follows participants through repeated assessments every 2 to 3 years, tracking changes from normal cognition to MCI and dementia, and exploring risk and protective factors. Participants engage in baseline and follow-up visits involving cognitive and mental health assessments using standardized scales like MMSE, MoCA, and CDR. Genetic analyses and biomarker measurements support diagnosis and disease understanding. The study also conducts randomized controlled trials of non-pharmacological treatments and education programs aimed at improving dementia awareness and care. Safety monitoring and informed consent are carefully managed, with ongoing follow-up to track disease progression and effects of interventions over time.

Age: 18Years +All Genders
65 locations
C

Actively Recruiting

Researchers are conducting a large observational study called the China HeadAche Disorders Registry CHAIRS to better understand primary headaches and medication-overuse headaches MOH in patients aged 12 years and older. The study aims to collect detailed information including biomarkers, brain imaging, cognitive and genetic data, as well as social, demographic, medical, and treatment-related data. Long-term follow-up is planned to observe outcomes related to headache disorders over many years. Participants include those with various types of primary headaches such as migraine, tension-type headache, new daily persistent headache, and MOH. The study includes behavioral follow-up visits at multiple time points monthly for the first 18 months, then at 24 months, and annually thereafter. Some participants are observed during routine clinical use of treatments like Yangxue Qingnao Granules, Erenumab, and Eptinezumab, with treatment decisions made by their physicians and outcomes tracked over 12 weeks or longer. Throughout the study, participants undergo periodic assessments including MRI scans, cognitive tests like the Montreal Cognitive Assessment MoCA and Mini-Mental State Exam MMSE, and questionnaires evaluating headache impact, anxiety, depression, quality of life, sleep quality, and fatigue. Data on headache frequency, severity, medication use, and biological samples are collected. Follow-up can extend up to 10 years, allowing researchers to monitor long-term changes and outcomes related to headache disorders and treatments.

Age: 12Years +All Genders
61 locations
E

Actively Recruiting

Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.

Age: 18Years +All GendersPhase 3
119 locations
S

Actively Recruiting

This research aims to evaluate whether combining cold atmospheric plasma CAP therapy with endovascular intervention can speed up wound healing and improve safety in adults aged 18 to 80 with diabetic foot ulcers DFUs complicated by lower extremity arterial blockage. The study compares CAP treatment plus standard care to placebo sham CAP plus standard care to investigate if CAP leads to greater ulcer area reduction and fewer adverse local symptoms. The trial is randomized, double-blind, and placebo-controlled to ensure reliable results. Participants receive either active CAP therapy or sham CAP therapy once daily for 10 days following successful balloon angioplasty of infrapopliteal arteries. CAP treatment involves applying CAP-activated gas for 25 minutes per session using a specialized device. Sham CAP uses identical equipment without plasma activation to maintain blinding. All participants continue to receive guideline-based standard diabetic foot ulcer care throughout the study. During the study, participants undergo daily wound assessments to measure ulcer size, infection signs, and pain levels. Quality of life questionnaires EQ-5D and SF-12 are completed at the start and at Week 4. The main outcome measured is the change in ulcer area from baseline through Day 10 and Week 4. Researchers also monitor pain scores, time to early healing, quality of life changes, and local adverse events. The study follow-up period is 4 weeks after randomization to evaluate efficacy and safety outcomes.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Critical limb ischemia is a severe form of peripheral arterial disease often seen in patients with diabetes, leading to painful ulcers, tissue damage, and sometimes amputation. This study investigates the use of cold atmospheric plasma CAP combined with endovascular intervention to treat diabetic foot ulcers complicated by lower extremity arterial occlusion. The study aims to assess whether this combination can improve healing outcomes and provide safer, more effective care for patients facing high risks from current therapies. Participants will receive successful infrapopliteal angioplasty to restore blood flow in affected arteries. They will then be randomly assigned to receive either CAP therapy or a sham procedure. CAP treatment involves daily sessions for the first five days, followed by every other day for a total of 13 sessions, each lasting about 25 minutes. The CAP device delivers ozone-rich plasma followed by nitric oxide-rich plasma to promote disinfection and healing. The sham procedure mimics the treatment sounds without producing plasma, ensuring blinding. Throughout the 21-day study period, researchers will monitor ulcer size, time to reduction, infection signs, pain levels, and quality of life using questionnaires. Safety will be tracked by recording skin irritation, bleeding, and burning sensations. Assessments include vascular imaging and clinical evaluations to measure treatment effects on wound healing and blood flow, with the goal of gathering evidence for CAPs role alongside endovascular techniques in diabetic foot care.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a renal artery radiofrequency ablation system guided by a three-dimensional cardiac electrophysiological mapping system for treating essential hypertension. This prospective, multi-center, randomized controlled trial includes both drug-control and sham-control studies to provide evidence for product registration, marketing, and clinical use. The study involves adults aged 18 to 70 with uncontrolled essential hypertension despite medication. Participants are assigned to different groups one receives percutaneous renal denervation using the FlashPoint radio-frequency ablation system guided by the Columbus 3D mapping system, while another undergoes a sham procedure consisting of renal artery angiography followed by continued antihypertensive medication. Drug-control research includes 65 subjects divided into renal artery ablation with drug treatment and drug treatment only groups. Sham-control research includes 180 subjects randomized 21 to renal artery ablation with drug treatment or sham procedure with drug treatment. Throughout the study, patients will have blood pressure measurements and medication assessments at 1, 2, 3, 4, 5, 6, and 12 months after the procedure. Urine samples will be collected for drug testing to check medication compliance. Researchers will monitor 24-hour ambulatory mean systolic blood pressure reduction and the incidence of major adverse events up to 6 months and 1 month respectively, along with various secondary outcomes related to blood pressure, drug burden, and safety events.

Age: 18Years - 70YearsAll GendersPhase Not Applicable
27 locations
S

Actively Recruiting

Researchers are evaluating Huaier granules to prevent the return and spread of colorectal cancer in patients who have undergone radical surgery. This open-label, real-world study aims to assess both the effectiveness and safety of Huaier granules in this patient group. The study is conducted at multiple sites and sponsored by Xi Shan Wang. Participants will be observed in one of three groups those receiving radiotherapy or chemotherapy alone, those receiving Huaier granules combined with radiotherapy or chemotherapy, and those receiving Huaier granules alone. The study follows patients after their surgery to monitor how these different approaches impact cancer recurrence and metastasis. During the 36-month study period, participants will undergo regular assessments to measure disease-free survival, overall survival, local recurrence-free survival, and distant metastasis-free survival. Researchers will also collect data on quality of life changes, adverse events, and immune function. Participants will be monitored closely to track their health and treatment effects throughout the study duration.

Age: 18Years - 75YearsAll Genders
22 locations
E

Actively Recruiting

Healthy Volunteer

Obesity greatly increases the risk of heart failure, and current treatments like caloric restriction, exercise, medications, or surgery may not be suitable for obese patients with heart failure. This research aims to study whether a combined approach using a diet management app and an intelligent weight scale can help obese patients with heart failure and reduced ejection fraction lose weight and improve their heart condition. The trial compares the effectiveness of a fully functional app and scale versus a limited-function version to assess their impact on heart failure outcomes and overall quality of life. Participants are randomly assigned to two groups one using a fully featured diet management app and intelligent weight scale with various monitoring tools and health metrics, and the other using a limited version of both. The full app tracks food intake, exercise, weight, and provides dietary analysis and recommendations, while the full scale measures body composition and vital signs. The limited versions offer fewer features. Participants use the app at every meal and weigh themselves daily for 12 months. During the study, participants will visit the clinic at 12 months for checkups. Researchers will evaluate outcomes such as a composite of death and heart failure hospitalizations over one year, changes in quality of life related to heart failure, and weight change. The trial includes monitoring of heart failure frailty and quality of life assessments at baseline, 3 months, and 1 year, with ongoing safety and condition tracking throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
26 locations
E

Actively Recruiting

Researchers are studying patients who have had an acute ischemic stroke caused by a blockage in a large blood vessel in the brain. The trial focuses on the safety and effectiveness of remote ischemic conditioning RIC as an additional treatment to improve recovery after endovascular thrombectomy, a procedure that removes the blockage. This research addresses the challenge that even when blood flow is restored, many patients still have poor outcomes or die, possibly due to brain injury during and after the procedure. The study compares three groups one receiving only endovascular thrombectomy and best medical care, a second group receiving thrombectomy plus RIC treatment for 14 days, and a third group receiving thrombectomy plus RIC for 30 days. RIC is a noninvasive device treatment where a cuff on the upper arm inflates and deflates in cycles, applied once before thrombectomy and twice daily afterward. Best medical management follows clinical guidelines for all groups. Participants will be monitored closely for 90 days after stroke. Researchers will assess recovery using the modified Rankin Scale to measure functional independence and will record neurological improvements, brain infarct size, adverse events, and quality of life. The study includes imaging, neurological exams, and safety checks at multiple time points, including 24 hours, 14 days, 72 hours, and 90 days post-treatment to evaluate the impact of RIC on stroke outcomes.

Age: 18Years +All GendersPhase 3
56 locations

1-10 of 12

1